KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer's disease.

James W Kupiec, Anton P Porsteinsson, Raymond S Turner, Suzanne Hendrix, Craig Mallinckrodt, Arifulla Khan, Ian Cohen, Jonathan Liss, Roger Clarnette, Kee Hyung Park, Antonio M Hernandez, Lindsay H Burns

J Prev Alzheimers Dis 13(3) 100469

PMID41500915
PMCIDPMC12988371
DOI10.1016/j.tjpad.2025.100469
发表日期2026-01-07
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:森林图/亚组分析图。
摘要

摘要

BACKGROUND: Soluble amyloid β1-42 (Aβ42) signals via the α7 nicotinic acetylcholine receptor to hyperphosphorylate tau in Alzheimer's disease (AD). Simufilam disrupts this pathogenic signaling by binding filamin A and disrupts its linkages with inflammatory receptors to reduce neuroinflammation. We assessed simufilam in two Phase 3 clinical trials in mild-to-moderate AD. METHODS: Participants were age 50-87 with Stage 4 or 5 CE, a mini-mental state exam (MMSE) ≥16 and ≤27 and a Clinical Dementia Rating Global Score (CDR-GS) of 0.5, 1 or 2. The criterion supporting AD pathology was plasma phosphorylated (p)-tau181 or prior amyloid PET. RETHINK randomized participants to simufilam 100 mg or placebo for 52 weeks. REFOCUS evaluated simufilam 50 and 100 mg versus placebo for 76 weeks. Co-primary endpoints were change from baseline on ADAS-Cog12 and ADCS-ADL. Sub-studies assessed exploratory plasma biomarkers and, in REFOCUS only, CSF and imaging biomarkers. RESULTS: Both trials failed to meet co-primary, secondary or exploratory biomarker endpoints. REFOCUS was terminated early, with 22% of participants still active in the trial. In the predefined mild subgroup in REFOCUS, simufilam was associated with slower cognitive decline than placebo through Week 64 (p = 0.019). This finding disappeared at Week 76 with 45% missing data and did not replicate in RETHINK. Favorable nominal exploratory post-hoc findings amongst participants with the highest half of screening plasma p-tau181 levels occurred in RETHINK but not REFOCUS. The plasma p-tau181 entry criterion did not reliably exclude amyloid PET negativity in the sub-study. CONCLUSIONS: Simufilam did not meet co-primary or secondary endpoints in these Phase 3 trials. Simufilam was safe and well tolerated. Trials registered at clinicaltrials.gov: NCT04994483 and NCT05026177.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 CONSORT diagram for RETHINK and REFOCUS trials.
非 KM Figure
Fig. 2Fig. 2 Change from baseline for ADAS-Cog12 in RETHINK and REFOCUS in ITT populations and mild and moderate subgroups. *p ≤ 0.05, **p = 0.01 in the corresponding group’s color. N = 714 and 494 for REFOCUS and RETHINK mild subgroups, respectively.
非 KM Figure